Enliven Therapeutics (ELVN) Retained Earnings (2019 - 2026)
Enliven Therapeutics (ELVN) posted Retained Earnings of -$370.8 million for Q1 2026, down 111115.87% sequentially from $334000.0 in Q4 2025, and down 36.32% YoY from -$582.3 million in Q1 2025.
Enliven Therapeutics (ELVN) Retained Earnings (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported Retained Earnings for 8 years, with the latest figure at -$370.8 million in Q1 2026.
- Quarterly Retained Earnings fell 36.32% year-over-year to -$370.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$370.8 million (down 36.32% YoY) and the FY2025 annual result came in at $334000.0, up 100.14% from the prior year.
- Retained Earnings slipped to -$370.8 million in Q1 2026 per ELVN's latest filing, from $334000.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $502.2 million in Q2 2024 and troughed at -$370.8 million in Q1 2026.
- A 5-year average of -$60.3 million and a median of -$97.6 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings slumped 16213700.0% in 2022, then soared 452496.4% in 2024.
- Over 5 years, Retained Earnings stood at $6.0 million in 2022, then soared by 6527.56% to $400.2 million in 2023, then sank by 160.84% to -$243.5 million in 2024, then jumped by 100.14% to $334000.0 in 2025, then sank by 111115.87% to -$370.8 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$370.8 million, $334000.0, and $221000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | 1.30 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Bn |
| Mar 31, 2026 | -370.79 Mn |
| Dec 31, 2025 | 334,000.00 |
| Sep 30, 2025 | 221,000.00 |
| Jun 30, 2025 | -297.40 Mn |
| Mar 31, 2025 | -272.00 Mn |
| Dec 31, 2024 | -243.47 Mn |
| Sep 30, 2024 | 242,000.00 |
| Jun 30, 2024 | 502.16 Mn |
| Mar 31, 2024 | -177.19 Mn |
| Dec 31, 2023 | 400.17 Mn |
| Sep 30, 2023 | -135.08 Mn |
| Jun 30, 2023 | -111,000.00 |
| Mar 31, 2023 | -97.60 Mn |
| Dec 31, 2022 | 6.04 Mn |
| Sep 30, 2022 | -178.19 Mn |
| Jun 30, 2022 | -35,000.00 |
| Mar 31, 2022 | -162.14 Mn |
| Dec 31, 2021 | -147.50 Mn |
| Sep 30, 2021 | -133.20 Mn |